New drugs, new challenges for dermatologists: mucocutaneous ulcers secondary to everolimus

AbstractEverolimus, a mammalian target of rapamycin inhibitor, is an emerging drug, which is being increasingly applied in oncology and solid organ transplantation. Oral ulcers are a frequent side effect associated with this immunosupressor. We report the case of a renal transplant recipient who dev...

Full description

Saved in:
Bibliographic Details
Main Authors: Victor Pavan Pasin (Author), Amanda Regio Pereira (Author), Kalline Andrade de Carvalho (Author), João Marcos Góes de Paiva (Author), Milvia Maria Simões e Silva Enokihara (Author), Adriana Maria Porro (Author)
Format: Book
Published: Sociedade Brasileira de Dermatologia, 2015-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_d834ed95983e464faab67f66cb970239
042 |a dc 
100 1 0 |a Victor Pavan Pasin  |e author 
700 1 0 |a Amanda Regio Pereira  |e author 
700 1 0 |a Kalline Andrade de Carvalho  |e author 
700 1 0 |a João Marcos Góes de Paiva  |e author 
700 1 0 |a Milvia Maria Simões e Silva Enokihara  |e author 
700 1 0 |a Adriana Maria Porro  |e author 
245 0 0 |a New drugs, new challenges for dermatologists: mucocutaneous ulcers secondary to everolimus 
260 |b Sociedade Brasileira de Dermatologia,   |c 2015-06-01T00:00:00Z. 
500 |a 0365-0596 
500 |a 10.1590/abd1806-4841.20153672 
520 |a AbstractEverolimus, a mammalian target of rapamycin inhibitor, is an emerging drug, which is being increasingly applied in oncology and solid organ transplantation. Oral ulcers are a frequent side effect associated with this immunosupressor. We report the case of a renal transplant recipient who developed disfiguring oral and perianal ulcers secondary to everolimus's toxicity. This is probably the first report of perianal involvement. Dermatologists need to be aware of the potential mucocutaneous adverse effects related to these new drugs that are becoming evermore common in our clinical practice. 
546 |a EN 
546 |a PT 
690 |a Drug eruptions 
690 |a Immunosuppressive agents 
690 |a Ulcer 
690 |a Dermatology 
690 |a RL1-803 
655 7 |a article  |2 local 
786 0 |n Anais Brasileiros de Dermatologia, Vol 90, Iss 3 suppl 1, Pp 165-167 (2015) 
787 0 |n http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962015000700165&tlng=en 
787 0 |n http://www.scielo.br/pdf/abd/v90n3s1/0365-0596-abd-90-03-s1-0165.pdf 
787 0 |n https://doaj.org/toc/0365-0596 
856 4 1 |u https://doaj.org/article/d834ed95983e464faab67f66cb970239  |z Connect to this object online.